Human cytomegalovirus (HCMV) is found worldwide and represents an important pathogen for immunocompromised individuals.
Currently approved treatments target the viral DNA polymerase.
Letermovir (AIC246, also known as MK-8228) is an oral, once-daily antiviral candidate for prevention and treatment of HCMV infection. It is a first in class molecule derived from a novel chemical class and is designed to inhibit the HCMV viral terminase.
In November 2017, AiCuris licensee Merck & Co, Inc. (MSD) announced that PREVYMISTM (letermovir) once-daily tablets for oral use and injection for intravenous infusion, received market approval by the U.S. Food and Drug Administration (FDA). PREVYMISTM is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
AiCuris and Merck & Co, Inc. (MSD), Kenilworth, NJ, USA, entered an exclusive worldwide license agreement for the investigational portfolio targeting HCMV in the year 2012. This agreement includes letermovir and an additional back-up candidate. Under the agreement, Merck & Co., Inc. (MSD), Kenilworth, NJ, USA, through a subsidiary, gained worldwide rights to develop and commercialize AiCuris' HCMV portfolio.
If you have further questions regarding partnering of our projects please contact: